A promising discovery could lead to better treatment for Hepatitis C

October 22, 2020

Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130 million people worldwide and nearly 250,000 Canadians. Antivirals exist but are expensive and not readily available in developing countries, where the disease is most prevalent.

Professor Terence Ndonyi Bukong and his team of virologists, in partnership with Professor Patrick Labonté, discovered this potential therapeutic target. They unveiled that the cellular protein RTN3 was involved in mediating an important pathway essential in Hepatitis C virus disease development, and progression. This promising discovery could lead to better treatments for the disease, which kills approximately 500,000 people annually.

Master of disguise

Normally, the immune system needs to recognize a virus to attack it and prevent infection. The Hepatitis C virus, however, is a master of disguise. It moves around, undetected, in exosomes, which are cell-released microvesicles vesicles that normally function in cellular communication, transport, and cellular waste disposal. This novel research revealed that the Hepatitis C viruses interact with a key area of the RTN3 protein utilizing it to insert their viral RNA into exosomes.

"We are the first researchers to demonstrate the exosomal role that this protein plays in hepatitis C pathogenesis," said Dr. Bukong, who led the study published in the journal PLOS One. "By identifying the areas of the protein that lead to the formation of an infectious exosome, we can now look for distinctive molecules that block the interaction with the viral RNA." He went on to say, "This would prevent the viral RNA from being able to enter exosomes and hide from the body's immune system."

The discovery of this interaction between the virus and the RTN3 protein opens the door to more research on other viruses that use exosomes to evade detection. "For example, studies have shown that HIV, Zika, and Hepatitis B viruses also hide inside exosomes. This disguise creates a problem for the optimal function of vaccines because even if antibodies are developed, they are unable to block viral infection or transmission," Dr. Bukong explained. "If the RTN3 protein also plays an important role in these other illnesses, it could help us make more effective treatments, and, potentially, more effective vaccines."
-end-
About the study

The researchers received funding from the Natural Sciences and Engineering Research Council of Canada (NSERC), the Canadian Institutes of Health Research (CIHR), the Institut national de la recherche scientifique (INRS), Alberta Innovates and the Fondation Armand-Frappier.

About INRS

INRS is a university dedicated exclusively to graduate level research and training. Since its creation in 1969, INRS has played an active role in Quebec's economic, social, and cultural development and is ranked first for research intensity in Quebec and second in Canada. INRS is made up of four interdisciplinary research and training centres in Quebec City, Montreal, Laval, and Varennes, with expertise in strategic sectors: Eau Terre Environnement, Énergie Matériaux Télécommunications, Urbanisation Culture Société, and Armand-Frappier Santé Biotechnologie. The INRS community includes more than 1,400 students, postdoctoral fellows, faculty members, and staff.

Source :
Audrey-Maude Vézina
Service des communications de l'INRS
418 254-2156
audrey-maude.vezina@inrs.ca

Institut national de la recherche scientifique - INRS

Related Hepatitis Articles from Brightsurf:

Busting Up the Infection Cycle of Hepatitis B
Researchers at the University of Delaware have gained new understanding of the virus that causes hepatitis B and the ''spiky ball'' that encloses its genetic blueprint.

Liver cancer: Awareness of hepatitis D must be raised
Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma.

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.

Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.

Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.

Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.

How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.

New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.

High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.

Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.

Read More: Hepatitis News and Hepatitis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.